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The prescription of antibiotics for patients with
acute exacerbations of chronic bronchitis (AECB)
is perceived by us to be excessive and sometimes
irrational. We read the opinion of Mensa and
Trilla [1] concerning antimicrobial therapy for
AECB with great interest. However, we consider
that these authors failed to correctly interpret the
beneﬁt of antibiotic treatment when only two of
three criteria were met (the so-called type II
exacerbations) [2] by stating that the beneﬁt was
reduced, albeit still signiﬁcant, for type II exacer-
bations [1]. Although antibiotic treatment con-
ferred marginal clinical advantage for type II
exacerbations, the question of whether these
differences were statistically signiﬁcant is not
addressed by the study of Anthonisen et al. [2].
In a randomised trial of patients requiring
mechanical ventilation [3], oﬂoxacin reduced the
mortality rate in hospitalised patients, but it is
important to emphasise that oﬂoxacin was espe-
cially beneﬁcial in preventing nosocomial pneu-
monia, which suggests that the improvement in
outcome was accomplished by a reduction in the
incidence of nosocomially acquired pneumonia,
as opposed to an impact on the primary disease
process [4].
Studies that use adequate statistical methods
to evaluate the impact of antibiotic treatment on
the mortality and prevention of pneumonia in
patients who do not require mechanical ventila-
tion are lacking. An observational study [5]
showed that patients with AECB who received
earlier treatment with bronchodilators and
inhaled steroids, with or without oral steroids,
and not simply antibiotic treatment as described
by Mensa and Trilla [1], had a shorter period of
exacerbations and a lower rate of hospitalisation.
However, as 93.6% of cases with exacerbations
were treated with antibiotics, this precludes a
meaningful statistical analysis of the effect of
antibiotic therapy on exacerbation outcomes [5].
After reviewing published studies, and on the
basis of our own experience in routine clinical
practice, we believe: (i) that patients who do not
require mechanical ventilation demonstrate a
small, but statistically signiﬁcant, improvement
attributable to antimicrobial therapy in terms of
outcome (greater symptom resolution, decreased
duration of exacerbation, increased lung function
[6–8]) and signiﬁcantly lowered relapse rates [9];
(ii) that patients with AECB should receive antibi-
otics if they have sputum purulence and either
increased dyspnoea or increased sputum volume,
or if the exacerbation is sufﬁciently severe that
mechanical ventilation (non-invasive or invasive)
is required [6–8,10]; and (iii) that the importance of
Pseudomonas aeruginosa in chronic obstructive
pulmonary disease (COPD) exacerbations is far
from clear, with no study to date having investi-
gated whether speciﬁc treatment for P. aeruginosa,
on the basis of risk-factors, alters the outcome
[10,11]. Thus, antimicrobial treatment targeted
against P. aeruginosa should be given only to
selected patients receiving mechanical ventilation
[10,12]. In our opinion, hospitalised patients who
do not require intensive care, and who do not have
bronchiectasis, do not require empirical antibiotic
treatment against P. aeruginosa, even if risk-factors
for Pseudomonas are present.
Finally, we agree with Mensa and Trilla [1] that
treatment of AECB with ﬂuoroquinolones
achieves clinical cure rates at least similar to
those achieved with other antibiotic groups
(b-lactams, macrolides) in patients who do not
require mechanical ventilation. We also agree that
patients with chronic bronchitis are at higher risk
of carrying resistant bacteria, depending on the
frequency of hospitalisations and the disease
severity. Therefore, although the importance of
P. aeruginosa in AECB is far from clear, at least in
patients who do not require intensive care, the
high rates of resistance to ciproﬂoxacin in
P. aeruginosa (30% in ambulatory patients in our
own hospital), and the secondary effects of ﬂuor-
oquinolones [13] or telithromycin [14], suggest
that broad-spectrum antibiotic therapy may not
be the answer. We maintain that the increase in
antibiotic-resistant microorganisms emphasises
the need to restrict the use of antibiotics to cases
in which they will make a signiﬁcant difference to
outcome.
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More evidence is required for short-term
treatment of exacerbations of chronic
obstructive pulmonary disease: 3 days or no
antibiotic at all?
10.1111/j.1469-0691.2007.01754.x
We read with interest the study by Roede et al. [1]
concerning the effectiveness of the short-term
treatment schedule of amoxycillin–clavulanic acid
for type 1 acute exacerbations of chronic obstruc-
tive pulmonary disease (COPD). As in a previous
study of pneumonia by the same group [2], an
attempt is made to answer the fundamental
question concerning the period for which anti-
microbial treatment should be administered in
cases of lower respiratory tract infection. In both
studies, the short 3-day schedule of antibiotic
treatment was as effective as the 10-day schedule,
when an improvement in symptoms was
observed at 3 days. This may be of even greater
interest in primary care, which is a setting in
which over-prescription is common, with a
signiﬁcant rate of non-compliance in cases of
mild and often self-limiting infections.
The results presented are of clinical interest.
However, we feel that the authors should have
been more cautious in formulating their conclu-
sions. A sample size of 225 patients was required
to demonstrate non-inferiority of the 3-day treat-
ment. Nevertheless, the authors concluded that
3-day therapy was an effective alternative to
10-day treatment, based on an analysis of only 46
subjects. Furthermore, the secondary outcome of
bacteriological efﬁcacy was based on an analysis
of only 19 patients [1]. It would have been more
appropriate to conclude that the results sugges-
ted a similar efﬁcacy and that further adequately
powered studies are required to demonstrate the
efﬁcacy of 3-day treatment.
Unlike pneumonia, infection causing an exacer-
bation of COPD is often self-limiting and does not
require antimicrobial treatment. It would there-
fore have been very interesting if a placebo group
had been included to demonstrate whether the
rate of cure in the other two antibiotic treatment
groups was different. Even in the landmark study
by Anthonisen et al. [3] of moderate-to-severe
COPD patients with a mean forced expiratory
volume in 1 s (FEV1) of 33.1%, 55% of the
patients were cured without antimicrobial
treatment. Interestingly, although the patients in
the study by Roede et al. were hospitalised, half
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